Theravance Biopharma Management

Management criteria checks 2/4

Theravance Biopharma's CEO is Rick Winningham, appointed in Jun 2014, has a tenure of 9.83 years. total yearly compensation is $4.32M, comprised of 24.3% salary and 75.7% bonuses, including company stock and options. directly owns 4.01% of the company’s shares, worth €16.60M. The average tenure of the management team and the board of directors is 1.8 years and 7.3 years respectively.

Key information

Rick Winningham

Chief executive officer

US$4.3m

Total compensation

CEO salary percentage	24.3%
CEO tenure	9.8yrs
CEO ownership	4.0%
Management average tenure	1.8yrs
Board average tenure	7.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Rick Winningham's remuneration changed compared to Theravance Biopharma's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$4m	US$1m	-US$55m
Sep 30 2023	n/a	n/a	-US$61m
Jun 30 2023	n/a	n/a	-US$68m
Mar 31 2023	n/a	n/a	-US$75m
Dec 31 2022	US$6m	US$1m	-US$93m
Sep 30 2022	n/a	n/a	-US$136m
Jun 30 2022	n/a	n/a	-US$196m
Mar 31 2022	n/a	n/a	-US$226m
Dec 31 2021	US$4m	US$1m	-US$265m
Sep 30 2021	n/a	n/a	-US$266m
Jun 30 2021	n/a	n/a	-US$264m
Mar 31 2021	n/a	n/a	-US$275m
Dec 31 2020	US$7m	US$1m	-US$295m
Sep 30 2020	n/a	n/a	-US$285m
Jun 30 2020	n/a	n/a	-US$270m
Mar 31 2020	n/a	n/a	-US$247m
Dec 31 2019	US$6m	US$984k	-US$236m
Sep 30 2019	n/a	n/a	-US$221m
Jun 30 2019	n/a	n/a	-US$222m
Mar 31 2019	n/a	n/a	-US$223m
Dec 31 2018	US$3m	US$957k	-US$216m
Sep 30 2018	n/a	n/a	-US$252m
Jun 30 2018	n/a	n/a	-US$260m
Mar 31 2018	n/a	n/a	-US$285m
Dec 31 2017	US$2m	US$933k	-US$285m

Compensation vs Market: Rick's total compensation ($USD4.32M) is above average for companies of similar size in the German market ($USD1.02M).

Compensation vs Earnings: Rick's compensation has been consistent with company performance over the past year.

CEO

Rick Winningham (63 yo)

9.8yrs

Tenure

US$4,318,531

Compensation

Mr. Rick E. Winningham, M.B.A., served as Chairman of Retrotope Inc. since February 2021 until January 2022 . He has been Lead Independent Director and Director of Jazz Pharmaceuticals Public Limited Compa...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Rick Winningham	Chairman & CEO	9.8yrs	US$4.32m	4.01% $ 16.6m
Aziz Sawaf	Senior VP & CFO	1.3yrs	US$1.39m	0.49% $ 2.0m
Stuart Knight	VP of IT&I and Chief Information Officer	no data	no data	no data
Gail Cohen	Vice President of Corporate Communications & Investor Relations	no data	no data	no data
Brett Grimaud	Senior VP	1.8yrs	no data	0.74% $ 3.1m
Rhonda Farnum	Chief Business Officer and Senior VP of Commercial & Medical Affairs	2.3yrs	US$942.81k	0.72% $ 3.0m
Stacy Pryce	Senior VP & Chief Strategy Officer	1.6yrs	no data	no data
Aine Miller	SVP of Dev.	no data	no data	0.35% $ 1.5m

1.8yrs

Average Tenure

53.5yo

Average Age

Experienced Management: 0TB's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Rick Winningham	Chairman & CEO	10.8yrs	US$4.32m	4.01% $ 16.6m
Eran Broshy	Independent Director	9.8yrs	US$205.14k	0.13% $ 518.1k
Burton Malkiel	Independent Director	10.5yrs	US$206.68k	0.22% $ 905.9k
Deepika Pakianathan	Independent Director	3.8yrs	US$207.68k	0.057% $ 236.1k
Dean Mitchell	Lead Independent Director	9.8yrs	US$211.73k	0.13% $ 518.1k
James Kelly	Independent Director	less than a year	US$43.10k	no data
Donal O'Connor	Independent Director	8.5yrs	US$195.80k	0.090% $ 373.4k
Susannah Gray	Independent Director	1.2yrs	US$346.47k	0.014% $ 57.5k
Laurie Smaldone Alsup	Independent Director	6.2yrs	US$197.68k	0.092% $ 380.1k
Jeremy Grant	Independent Director	less than a year	US$168.36k	0% $ 0

7.3yrs

Average Tenure

64yo

Average Age

Experienced Board: 0TB's board of directors are considered experienced (7.3 years average tenure).

Theravance Biopharma Management

Management criteria checks 2/4

Key information

Recent management updates

Theravance Biopharma, Inc. Appoints Jeremy Grant as Independent Director

Theravance Biopharma, Inc. Announces Board Changes

Theravance Biopharma, Inc., Annual General Meeting, May 08, 2024

Chairman & CEO recently sold €525k worth of stock

Theravance Biopharma, Inc. Announces Chief Financial Officer Changes

Insufficient new directors

Recent updates

Forecast to breakeven in 2026

Full year 2023 earnings released: US$1.00 loss per share (vs US$1.26 loss in FY 2022)

Theravance Biopharma, Inc. to Report Q4, 2023 Results on Feb 26, 2024

New major risk - Financial position

Theravance Biopharma Announces Results from the Phase 4 YUPELRI®? PIFR-2 Study in Patients with Severe to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

Forecast to breakeven in 2026

Theravance Biopharma, Inc. Appoints Jeremy Grant as Independent Director

Theravance Biopharma, Inc. Announces Board Changes

Theravance Biopharma, Inc., Annual General Meeting, May 08, 2024

Third quarter 2023 earnings released: US$0.17 loss per share (vs US$0.21 loss in 3Q 2022)

Theravance Biopharma, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Theravance Biopharma to Present New Ampreloxetine Data at the 2023 International Congress of Parkinson's Disease and Movement Disorders

New minor risk - Financial position

Second quarter 2023 earnings released: US$0.28 loss per share (vs US$0.11 loss in 2Q 2022)

Theravance Biopharma, Inc. to Report Q2, 2023 Results on Aug 07, 2023

Forecast to breakeven in 2024

Full year 2022 earnings released: US$1.26 loss per share (vs US$2.87 loss in FY 2021)

No longer forecast to breakeven

Chairman & CEO recently sold €525k worth of stock

Theravance Biopharma, Inc. Announces Chief Financial Officer Changes

Insufficient new directors

Third quarter 2022 earnings released: US$0.21 loss per share (vs US$0.48 loss in 3Q 2021)

Theravance Biopharma, Inc. Presents New Ampreloxetine Data in Neurogenic Orthostatic Hypotension

Theravance Biopharma, Inc. to Report Q3, 2022 Results on Nov 07, 2022

Theravance Biopharma, Inc. (NasdaqGM:TBPH) announces an Equity Buyback for $60 million worth of its shares.

Theravance Biopharma, Inc. (NasdaqGM:TBPH) announces an Equity Buyback for $250 million worth of its shares.

Theravance Biopharma, Inc. (NasdaqGM:TBPH) announces an Equity Buyback for $250 million worth of its shares.

Insider recently sold €130k worth of stock

Forecast breakeven date pushed back to 2024

Forecast breakeven date pushed back to 2024

Second quarter 2022 earnings released: US$0.11 loss per share (vs US$0.80 loss in 2Q 2021)

Theravance Biopharma, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Royalty Pharma plc (NasdaqGS:RPRX) completed the acquisition of 85% stake in Theravance Respiratory Company, LLC.

Forecast breakeven date pushed back to 2023

Royalty Pharma plc (NasdaqGS:RPRX) entered into a definitive agreement to acquire unknown stake in Theravance Respiratory Company, LLC for $1.4 billion.

Royalty Pharma plc (NasdaqGS:RPRX) entered into a definitive agreement to acquire unknown stake in Theravance Respiratory Company, LLC for $1.4 billion.

First quarter 2022 earnings released: US$0.34 loss per share (vs US$1.24 loss in 1Q 2021)

Theravance Biopharma, Inc. to Report Q1, 2022 Results on May 05, 2022

Insufficient new directors

Theravance Biopharma, Inc. Announces Results from Study 0170

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Theravance Biopharma, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Theravance Biopharma, Inc. Announces Enrollment of First Patient in YUPELRI® Phase 4 Study

Senior Vice President of Technical Operations Vijay Sabesan has left the company

Third quarter 2021 earnings released: US$0.48 loss per share (vs US$1.16 loss in 3Q 2020)

Forecast to breakeven in 2023

Independent Director Robert Gunderson has left the company

Independent Director George Whitesides has left the company

Theravance Biopharma, Inc. Announces Top-Line Results from Phase 2B Dose-Finding Induction Study of Izencitinib in Patients with Ulcerative Colitis

Second quarter 2021 earnings released: US$0.80 loss per share (vs US$1.00 loss in 2Q 2020)

Theravance Biopharma, Inc. has completed a Follow-on Equity Offering in the amount of $100.5 million.

Theravance Biopharma, Inc. Announces Top-Line Results from Its Phase 2 Study of 3 Mg Once-Daily Nezulcitinib

First quarter 2021 earnings released: US$1.24 loss per share (vs US$1.40 loss in 1Q 2020)

Senior VP & Chief Medical Officer has left the company

Theravance Biopharma, Inc. Announces Resignation of Brett Haumann as Senior Vice President and Chief Medical Officer Effective April 5, 2021

Insider recently sold €149k worth of stock

Full year 2020 earnings released: US$4.46 loss per share (vs US$4.25 loss in FY 2019)

Revenue misses expectations

Theravance Biopharma, Inc. to Report Q4, 2020 Results on Feb 23, 2021

New 90-day high: €16.20

Insider recently sold €120k worth of stock

Insider recently sold €63k worth of stock

Third quarter 2020 earnings released: US$1.16 loss per share

Revenue beats expectations

Theravance Biopharma, Inc., Annual General Meeting, Apr 27, 2021

New 90-day low: €13.70

Senior VP & Chief Medical Officer recently sold €388.2k worth of stock

New 90-day low - €13.80

Earnings released